Phase 3 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who are experiencing cardiogenic shock (a serious condition where the heart cannot pump enough blood to meet the body's needs)
- People whose blood volume levels are considered adequate by their medical team
- People who have been receiving a medication called norepinephrine (to keep blood pressure at a safe level) for at least 3 hours but less than 24 hours, at a dose below a specific threshold set by the trial, and/or have been receiving a heart-support medication called dobutamine for at least 3 hours but less than 24 hours
- People showing at least one sign that their body tissues are not getting enough blood flow — such as elevated lactate levels in the blood, skin mottling, slow capillary refill, very low urine output, or low oxygen levels in the blood — detected within the 24 hours before joining the trial
Who may not be able to join:
- People whose heart has been stunned as a result of a cardiac arrest that was caused by something other than a heart condition
- People who need, or are expected to need within 6 hours, a type of life support machine that takes over the work of the heart and lungs (confirm with trial site)
- People already using certain mechanical heart-support devices (VA-ECMO, IMPELLA, or LVAD)
- People with long-term kidney failure who are already on dialysis
- People whose heart condition is caused by poisoning with a substance toxic to the heart
- People whose heart condition is caused by a severe infection (septic cardiomyopathy)
- People who have received a medication called levosimendan within the past 15 days
- People who have had a cardiac arrest with a non-shockable heart rhythm
- People who had a cardiac arrest where the heart received no blood flow for more than 3 minutes before resuscitation began
- People who had a cardiac arrest where the length of time with no blood flow is not known
- People whose total cardiac arrest time (both the no-flow and low-flow periods combined) exceeded 45 minutes
- People showing signs of severe brain damage, specifically fixed and dilated pupils
- People considered to be in a terminal state on the day of enrolment
- People with an irreversible neurological condition
- People with a known allergy or sensitivity to levosimendan, placebo, or any of their ingredients
- People who are pregnant, giving birth, or breastfeeding
- People under the age of 18
- People who are currently detained by a judicial or administrative order
- Adults who are under a legal protection arrangement, such as guardianship or conservatorship
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clément DELMAS, Dr, University Hospital, Toulouse
Phone: +33 3 83 15 40 84
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of All-cause mortality; Proportion of Extra Corporel Life Support implantation; Proportion of Dialysis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.